Gastrointestinal Cancers Articles & Analysis
11 news found
” Headquartered in Cardiff, Wales, and backed by a team of scientists, engineers, and manufacturing technicians, Cellesce technology produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids — with pancreatic and lung organoids under development ...
Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101. ...
The amended license will enable Chimeric to manufacture clinical-grade lentiviral vector for use in its planned phase 1 study of CHM 2101 (CDH17 CAR T) for gastrointestinal cancers. In addition, Chimeric is able to cross-reference regulatory information on file with the US FDA to facilitate filing of an Investigational New Drug (IND) for CHM 2101. ...
More than 50 health conditions are planned for Health Unmuted including diabetes, multiple sclerosis, breast cancer and gastrointestinal conditions. About Mission Based Media Ltd. ...
The results from the myCare-004 clinical study were featured in a poster session as part of the 2022 ASCO Annual Meeting during the Gastrointestinal Cancer – Gastroesophageal Pancreatic and Hepatobiliary Track and available online as Abstract 4064. “This study confirmed that there are many dysregulated signaling pathways responsible for hallmark ...
(Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. ...
Oral Presentation Title: ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC) Abstract Number: 6005 Presenter: Carryn M. Anderson, M.D., University of Iowa Hospitals & Clinics Session Title: Head and Neck Cancer ...
(Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium ...
Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place Jan. 20-22, 2022. The poster highlights clinical data ...
ByAlkermes
Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the first patient was dosed in the KEYNOTE-B79 Phase 1b trial (NCT04991948). ...
Researchers and oncologists took note, not due to the attention-grabbing headlines, but because their focus was to pair the decoded cannabis genome research with sequencing of the DNA of cancer tumors for new research on cannabis and cancer. The news was a celebration of the completion of a key component for those striving to research the affects of using ...